Key facts
- This page summarizes Aine Miller's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Aug 2026, 18:04.
Aine Miller - 20 Aug 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)
- Reporting relationship
- SVP, DEV & HEAD OF IRE OFFICE
- Issuer ticker
- TBPH
- Reported as of
- 20 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Aug 2026, 18:04:40 UTC
- Prior SEC filing
- 23 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett A Grimaud, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Aine Miller filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 24 Aug 2026.
Change
- Previous filing in this sequence was filed on 23 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002012524
Primary reporting owner
Miller Aine
- Relationship
- SVP, DEV & HEAD OF IRE OFFICE
- Address
- C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO
- Signature
- /s/ Brett A Grimaud, Attorney-in-Fact
- Signature date
- 24 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBPH
transaction
Ordinary Shares
Tax liability
- Transaction value
- Shares
- -6,258
- Change %
- -3.2%
- Price
- $16.95*
- Shares after
- 189,826
- Date
- 20 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.